The board of directors of the Company (the “Board”) is pleased to announce that the Group has submitted the pre-application for clinical trials for novel-process highly-effective human diploid rabies vaccine on March 24, 2024. Currently, there is a lack of effective clinical treatment for rabies, and therefore post exposure prevention is crucial. The main preventive measures are inoculation of human rabies vaccine and injection of passive immunization agents. The human diploid cell rabies vaccine has natural safety advantages and a broad market space.

The novel-process highly-effective human diploid rabies vaccine developed by the Group became the first to break through the technical bottleneck of low virus titer and small yield in the traditional process, with optimized and innovated purification process, which has notably improved product quality and safety as compared with similar marketed products in China, and has the production capacity for large-scale commercialization.

The Group has completed the construction of its workshop for novel-process highly-effective human diploid rabies vaccine, which has sufficient production capacity and meets international standards, and the equipment is currently being debugged and verified. As the second largest supplier of rabies vaccines globally, the Group spearheads the in-depth technological iteration of rabies vaccines in the world, and will deliver rabies vaccine products with better quality and higher safety in the market after the iterative rabies series vaccines are marketed, so that new productive forces will be achieved in the industry.